Page last updated: 2024-10-21

vanilmandelic acid and Depressive Disorder, Major

vanilmandelic acid has been researched along with Depressive Disorder, Major in 1 studies

Vanilmandelic Acid: A 3-O-methyl ether of 3,4-dihydroxymandelic acid. It is an end-stage metabolite of CATECHOLAMINES; EPINEPHRINE; and NOREPINEPHRINE.
vanillylmandelic acid : An aromatic ether that is the 3-O-methyl ether of 3,4-dihydroxymandelic acid.

Depressive Disorder, Major: Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Wang, L1
Yang, P1
Yang, C1
Yang, D1
Wu, X1
Cao, T1
Zeng, C1
Chen, Q1
Zhang, S1
Zhu, Z1
Jiao, S1
Cai, H1

Other Studies

1 other study available for vanilmandelic acid and Depressive Disorder, Major

ArticleYear
Disturbance of neurotransmitter metabolism in drug-naïve, first-episode major depressive disorder: a comparative study on adult and adolescent cohorts.
    European archives of psychiatry and clinical neuroscience, 2022, Volume: 272, Issue:7

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adult; Biomarkers; Depressive Disorder, Major; Dopamine;

2022